Previous studies have shown that blockade of the HVEM/LIGHT interaction with the use of antibodies or soluble receptors can reduce allogeneic immune responses, improve graft survival, and mitigate graft-versus-host disease (GVHD)4,5. Here, TNFRSF14 is linked to graft versus host disease.